Biohaven Ltd - BHVN Net Assets per Single Share

Biohaven Ltd. (BHVN) - corporate logo

Management under Vlad Coric enjoys the unconditional trust of shareholders due to its ability to generate capital and the active expansion of R&D pipelines. The market trend visualized in monetary terms, with a value of 0.08, reinforces the success of Biohaven Ltd. (BHVN) in creating the MoDE platform and developing the epilepsy treatment BHV-7000. This non-cyclical biopharmaceutical company relies on its patent schedule, demonstrating stable demand even amidst economic turmoil.

Biohaven Ltd (BHVN) Equity per Share: for the period 07/04/2022 - 10/27/2026

biohavenpharma.com - analytical breakdowns and key metrics (BHVN)

- price and consensus price forecast:
Stock Quotes Biohaven Pharmaceutical|BHVN - Price Target Chart
- market capitalization data:
Market Value Biohaven Ltd.|BHVN - Business Value
- book capitalization data:
Net Assets per Single Share Biohaven|BHVN - Accounting Capitalization|Market Capitalization to Book Value Ratio biohavenpharma.com|BHVN - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Biohaven Ltd.|BHVN - Long-Term Debt to Capital|Short-Term Debt to Equity Biohaven|BHVN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Biohaven Ltd.
Fundamental company valuation:Biohaven Pharmaceutical, BHVN
Manufactured products of Biohaven

Investors often seek capital protection mechanisms during periods of market volatility. For Biohaven Ltd. (BHVN), a significant liquidity reserve supporting new neurological developments serves as such a stabilizer. Analyzing the accounting data for the share price, we see a net equity per share equal to 0.08. This metric reflects the asset's actual tangible backing after deducting all liabilities. The growth of this indicator confirms the fundamental stability of the portfolio.

Competitors of Biohaven Ltd. (BHVN)

BIIB - Accounting Value per Share|NBIX: Net Assets per Single Share|Net Assets per Single Share Regencell Bioscience|AXSM (axsome.com) - Equity per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Praxis Corp (PRAX) - Net Asset Value per Share|Book Value per Share Anavex Life Sciences|Net Assets per Single Share ceribell.com|PRTA (Prothena Biosciences) - Book Value per Share|Net Assets per Share ALEC (alector.com)|ANNX: Net Assets per Single Share|Net Asset Value per Share Omeros Corp OMER|Book Value per Share Neurogene Inc. (NGNE)|ACIU - Accounting Value of a Share|VYGR: Book Value per Share|Book Value per Share Neumora|Accounting Value per Share Scilex Holding Co.|Net Assets per Single Share Tevogen Bio Inc.|Alpha Cognition - Book Value per Share|Net Asset Value per Share CGTX (Cognition Therapeutics Inc.)|IKT - Net Assets per Single Share|SAVA - Equity per Share|Accounting Value per Share Assertio Therapeutics (ASRT)|COYA: Accounting Value of a Share|vistagen.com (VTGN) - Net Assets per Single Share|Net Assets per Single Share Ovid Therapeutics|Acumen Pharmaceuticals, Inc. (ABOS) - Accounting Value per Share|Book Price of a Share CervoMed, Inc.|Book Value per Share Alterity Therapeutics ATHE|Equity per Share clene.com CLNN|Accounting Value per Share PEPG|Net Assets per Share Jupiter Neurosciences, Inc. JUNS|RLMD - Book Value per Share|ANVS - Net Assets per Single Share|Book Value per Share gracetx.com GRCE|Accounting Value of a Share Firefly Neuro|Accounting Value per Share ANEW Medical|Net Assets per Single Share NRSN|Net Assets per Single Share Reviva Pharmaceuticals Holdings, Inc. RVPH|Equity per Share MTVA (metaviatx.com)|NRXS - Net Assets per Single Share|Equity per Share Helius Medical Technologies, Inc. HSDT|PASG (Passage Bio Corp) - Book Value per Share|Neuphoria Therapeutics Inc. (NEUP) - Net Asset Value per Share|NERV: Accounting Value per Share|ATHA (Athira Pharma Inc) - Book Value per Share|ADXN - Net Assets per Single Share|Accounting Value of a Share ALZN|Cyclerion Therapeutics - Net Assets per Single Share|Net Asset Value per Share protagenic.com (PTIX)|Book Value per Share Pasithea Therapeutics Corp. KTTA|Net Assets per Single Share Cortigent Inc CRGT|Book Value per Share ATXI (Avenue Therapeutics, Inc)|BCLI: Net Assets per Share|Net Assets per Single Share CARA|chromocell.com (CHRO) - Net Asset Value per Share|ELYM - Book Value per Share|Accounting Value of a Share Intra-Cellular|Book Value per Share LBPH|Book Value per Share Marinus Pharma MRNS|Accounting Value per Share NKGen Biotech, Inc. NKGN|Net Assets per Single Share neurobopharma.com NRBO|SAGE (Sage Therapeutics) - Book Value per Share|SNPX: Net Asset Value per Share|Net Assets per Single Share Trevena, Inc|Equity per Share Vigil Neuroscience, Inc.|WENA - Accounting Value per Share|Accounting Value of a Share CERE